Phase 4 Atrial Fibrillation Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older
- People who have atrial fibrillation or atrial flutter and whose doctor has determined they need to take a type of blood thinner called a direct-acting oral anticoagulant (DOAC) for at least 12 months
- People who have had a successful procedure to open blocked heart arteries (using a small tube called a stent, inserted through the skin) within the past 7 days, with no other blocked arteries left that still need to be treated
- People who have not experienced serious complications after that procedure, such as new chest pain thought to be related to the heart, a blocked stent, or new stroke-like symptoms
- People who have given written agreement to take part in the trial
Who may not be able to join:
- People who have another planned procedure to open blocked heart arteries (a valve procedure may be allowed if it takes place more than 30 days after the qualifying heart procedure)
- People who have had a procedure to reset their heart rhythm (cardioversion) in the past month, or who have one planned
- People who have had a procedure to treat their atrial fibrillation using heat or cold energy (ablation) in the past 2 months, or who have one planned
- People who have previously had an artificial mechanical heart valve implanted
- People who have a blood clot in the leg or lung, a significant narrowing of a heart valve called the mitral valve, or another condition (besides atrial fibrillation) that requires long-term blood thinners
- People who have had a stroke in the past month
- People whose blood pressure is dangerously low, who need continuous medication to keep the heart pumping, or who require a mechanical device to help the heart work
- People with very high uncontrolled blood pressure (top number at or above 180 mmHg and/or bottom number at or above 120 mmHg)
- People with very poor kidney function or who are on dialysis
- People with moderate or severe liver disease, or any liver condition that affects blood clotting
- People who are known to be allergic to or cannot safely take blood thinners or antiplatelet medications (such as aspirin or a related drug called a P2Y12 inhibitor)
- People with very low platelet counts or very low haemoglobin levels on recent blood tests
- People who are pregnant or breastfeeding
- People with another serious non-heart condition where life expectancy is less than one year
- People who have planned surgery, including open-heart bypass surgery, within the next 6 months
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Stephan Windecker, Prof, Bern University Hospital, Department of Cardiology
Phone: +41 31 632 44 97
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The number of participants with a major adverse cardiac or cerebral events (MACCE), defined as the composite of death from any cause, myocardial infarction, stroke or non-central nervous system (non-CNS) systemic embolism; The number of participants with a major or clinically relevant non-major bleeding (MCB), defined according to the International Society of Thrombosis and Haemostasis (ISTH) criteria
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.